Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone
In Brief: FCRF Contract Hopefuls Make Oral Presentation; Jane Rowley To Deliver Karnofsky Lecture
Will Latest Report By Rosenberg Stir Up Critics? Some DCT Board Members Defend the Press
“Official Chronology” Of Gall/Montagnier Finding Agreed On; Royalties to Fund AIDS research
Spartanburg CCOP Makes the List
WETA Relents Will Air Documentary
Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages